Market Place
Sourcing Support
Lupin receives FDA tentative approval for HIV treatment generic
07 Dec 2024 //
EXPRESSPHARMA
FDA gives tentative approval to Lupin’s for treat type 2 diabetes
30 Nov 2024 //
FINANCIALXPRESS
Lupin’s Humrahi Diabetes Support Program Expands To Heart Health
28 Nov 2024 //
FINANCIALXPRESS
Enforcement Report - Week of November 27, 2024
27 Nov 2024 //
FDA
Lupin recalls over 6 lakh bottles of hypertension drug in US
26 Nov 2024 //
ECONOMICTIMES
Lupin’s ESG score rises to 76 in S&P Global ESG Ratings
25 Nov 2024 //
EXPRESSPHARMA
Lupin and NAPCON host Walkathon to raise COPD awareness
22 Nov 2024 //
EXPRESSPHARMA
Lupin receives FDA approval for generic version of Adderall XR
21 Nov 2024 //
EXPRESSPHARMA
Lupin launches Bumetanide Injection USP in US
20 Nov 2024 //
PRESS RELEASE
Lupin launches Humrahi with focus on diabetes and heart health
18 Nov 2024 //
EXPRESSPHARMA
Lupin receives tentative FDA approval for Raltegravir tablets
11 Nov 2024 //
EXPRESSPHARMA
Lupin Eyes Double-Digit Growth, Focuses on US Market in FY25
09 Nov 2024 //
CNBCTV
Lupin CFO: Medicine Business Benefits from Supply Chain Diversify
08 Nov 2024 //
CNBC
Lupin Develops Inhalers with Near-Zero Global Warming Propellants
28 Oct 2024 //
PR NEWSWIRE
DoP Rejects Review Applications on Metoprolol Pricing
24 Oct 2024 //
PHARMABIZ
Lupin appoints Claus Jepsen as President of Global Specialty
22 Oct 2024 //
EXPRESSPHARMA
Lupin launches Aptivate Achi Bhookh Fest in Mumbai and Suburbs
16 Oct 2024 //
INDPHARMAPOST
Lupin launches first generic of Pred Forte in the US
16 Oct 2024 //
EXPRESSPHARMA
Lupin and Scope sign agreement for Optase in Mexico
08 Oct 2024 //
INDPHARMAPOST
Lupin`s Pune-based biotech facility gets 5 observations from US FDA
05 Oct 2024 //
BUSINESS STD
Lupin acquires 9 brands of Medical Nutritional Institute in Africa
05 Oct 2024 //
EXPRESSPHARMA
Aytu Partners With Lupin To Commercialize ADHD Drugs In Canada
01 Oct 2024 //
ACCESSWIRE
Lupin Signs Distribution Agreement With Scope Ophthalmics
01 Oct 2024 //
EXPRESSPHARMA
Lupin Ties Up With Scope Opthalmics To Market Eyecare Products
30 Sep 2024 //
ECONOMICTIMES
Lupin inks pact with Celnova Pharma for distribution of drug
28 Sep 2024 //
ECONOMICTIMES
Lupin gets US FDA nod for Bumetanide Injection, USP
19 Sep 2024 //
EXPRESSPHARMA
Lupin partners with Takeda to commercialise Vonoprazan
18 Sep 2024 //
EXPRESSPHARMA
Sunsure Energy and Lupin sign 21 MW solar power purchase agreement
12 Sep 2024 //
EXPRESS PHARMA
Lupin launches Mirabegron Extended-Release Tablets in the US
04 Sep 2024 //
EXPRESSPHARMA
Lupin, Dr Reddy`s recall products in US due to manufacturing issues
04 Sep 2024 //
BUSINESS STANDARD
Lupin introduces doxorubicin hydrochloride liposome injection in US
29 Aug 2024 //
PHARMABIZ
Lupin receives U.S. FDA approval for Brimonidine Tartrate Ophthalmic Solution
28 Aug 2024 //
EXPRESSPHARMA
Lupin`s Generics Brimonidine Tartrate Receives Approval in US
26 Aug 2024 //
FDA
Lupin gains Health Canada approval for biosimilar Pegfilgrastim
24 Aug 2024 //
EXPRESSPHARMA
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
12 Aug 2024 //
INDIANPHARMAPOST
Lupin shares jump over 6 pc; hit 52-week high after strong June qtr earnings
07 Aug 2024 //
ECONOMICTIMES
Lupin completes Phase 3 Trials for Lucentis Biosimilar
06 Aug 2024 //
EXPRESSPHARMA
Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
06 Aug 2024 //
#N/A
Lupin`s Generics Prednisolone Acetate Receives Approval in US
02 Aug 2024 //
FDA
Lupin receives US FDA tentative marketing approval for generic Descovy tablets
31 Jul 2024 //
PHARMABIZ
Generic HIV raltegravir medicines approved
22 Jul 2024 //
EUROPEAN PHARMACEUTICAL REVIEW
Lupin And Huons Sign Agreement For Cyclosporine Ophthalmic In Mexico
22 Jul 2024 //
INDIANPHARMAPOST
Lupin Divests US Women`s Health Specialty Business To Evofem
15 Jul 2024 //
PR NEWSWIRE
Lupin receives EIR from U.S. FDA for its Dabhasa facility
15 Jul 2024 //
EXPRESSPHARMA
Lupin divests women’s health specialty business in US to Evofem for $84 million
15 Jul 2024 //
MONEY CONTROL
Lupin receives EIR from USFDA for its Dabhasa facility
13 Jul 2024 //
INDIANPHARMAPOST
Lupin receives FDA tentative marketing approval for generic Trijardy XR tablets
09 Jul 2024 //
PHARMABIZ
Lupin Pharm`s Generic Empagliflozin Receives Tentative Approval in US
08 Jul 2024 //
FDA
Lupin Pharm`s Generic Olopatadine HCL Receives Tentative Approval in US
26 Jun 2024 //
FDA
Enforcement Report - Week of June 26, 2024
26 Jun 2024 //
FDA
Lupin Appoints Abdelaziz Toumi As CEO Of API CDMO Subsidiary
24 Jun 2024 //
CONTRACT PHARMA
Lupin receives EIR from US FDA for its Somerset manufacturing facility
24 Jun 2024 //
PHARMABIZ
Lupin and Fuji Sign Agreement for Nextstellis in Vietnam, Philippines
17 Jun 2024 //
INDINPHARMAPOST
USFDA inspection of Lupin’s Nagpur injectable with zero 483 observations
14 Jun 2024 //
INDIANPHARMAPOST
Thailand announces investment worth $1.54 B in biochemicals, data centres
14 Jun 2024 //
BIOSPECTRUM ASIA
Lupin Atlantis completes acquisition of two brands from Sanofi in Eu & Canada
05 Jun 2024 //
PHARMABIZ
Enforcement Report - Week of May 22, 2024
22 May 2024 //
FDA
Lupin`s Somerset facility gets Form-483 with six observations US FDA inspection
20 May 2024 //
BUSINESS-STANDARD
Lupin achieves significant milestone with ISO 14001 & ISO 45001 certification
15 May 2024 //
PHARMABIZ
Lupin appoints Jeffrey Kindler, Alfonso `Chito` Zulueta as Independent directors
09 May 2024 //
MONEYCONTROL
